CVS
OrganizationRelationship Network
EFTA00032738.pdf
This document is a Law360 email newsletter from June 17, 2021, summarizing various legal news stories in New York. A key item reports that Ghislaine Maxwell's attorneys complained to a judge about prison conditions, specifically alleging that feces rained down in her cell and guards listened to privileged conversations. Other stories cover Greenberg Traurig lobbying for a bill aiding a Russian oligarch, various financial settlements, and legal industry news.
HOUSE_OVERSIGHT_023087.jpg
This document is page 19 of a 'Equity Strategy Focus Point' report produced by Bank of America Merrill Lynch on January 29, 2017. It presents a table of S&P 500 companies identified as potential beneficiaries of a lower US corporate tax rate due to their high effective tax rates and low foreign sales exposure. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production to the House Oversight Committee.
HOUSE_OVERSIGHT_024885.jpg
A Cowen 'Collaborative Insights' financial research report dated February 25, 2019, authored by Chen. The document analyzes the market entry of Cannabidiol (CBD) into mass retail, predicting that the beauty sector (Luxury and Prestige) will adopt it before broadline retailers like Walmart or Target. It details specific moves by Barneys, Neiman Marcus, DSW, and Sephora. The document bears the Bates stamp HOUSE_OVERSIGHT_024885, indicating it was part of a document production to the House Oversight Committee, likely incidental to a larger financial investigation as no specific Epstein-related individuals are mentioned in the text.
HOUSE_OVERSIGHT_024879.jpg
This document is page 63 of a Cowen Collaborative Insights report dated February 25, 2019, authored by an analyst named Rhyee. It analyzes the market trends of CBD products in pharmacies, noting that independent pharmacies are adopting CBD sales faster than large chains like CVS or Walgreens due to high margins and demand. The report highlights that while Walgreens (WBA) does not sell CBD in the US, its UK subsidiary, Boots, does sell Dragonfly brand CBD oils, as illustrated by a website screenshot included in the report. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was produced during a congressional investigation.
HOUSE_OVERSIGHT_024875.jpg
This document is page 59 of a Cowen Collaborative Insights financial report dated February 25, 2019, analyzing the Cannabis/CBD market. It presents comparative financial data (Revenue, Gross Profit, and Gross Margin) for several companies including Charlotte's Web, CV Sciences, and Level Brands. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a congressional investigation document production.
HOUSE_OVERSIGHT_024820.jpg
This document is page 4 of a Cowen 'Collaborative Insights' market research report dated February 25, 2019. It analyzes the market for cannabinoids (CBD), focusing on synthetic biology production methods, laboratory testing opportunities for life science companies, and the perspectives of drug retailers and insurance payors regarding coverage and sales. The document bears a 'HOUSE_OVERSIGHT_024820' Bates stamp, indicating it was part of a production to the House Oversight Committee, likely related to financial investigations.
HOUSE_OVERSIGHT_025890.jpg
This document appears to be a printout of a news article or press release compilation regarding the FDA approval and market analysis of the Regeneron/Sanofi cholesterol drug, Praluent. It details financial projections, physician surveys, and quotes from executives at Regeneron, Sanofi, and CVS Caremark regarding pricing and accessibility. While the document bears a House Oversight stamp and mentions Donald Trump in a disconnected headline, the content focuses entirely on the pharmaceutical industry.
HOUSE_OVERSIGHT_025889.jpg
This document discusses the approval, benefits, and high cost of a new cholesterol-lowering drug called Praluent, noting its potential expense concerns raised by CVS Caremark executive Troy Brennan. It details the FDA's approval criteria, focusing on patients with genetic conditions or previous heart disease, and mentions the pricing strategy by Regeneron and Sanofi amidst competition from Amgen. The bottom half of the page lists "Recommended by Forbes" article links.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity